Pandion Therapeutics, Inc. reported unaudited consolidated financial results for the second quarter and six months ended June 30, 2020. For the quarter, the company reported revenue was $1,955,000. Loss from operations was $9,202,000 against $5,774,000 a year ago. Net loss was $9,237,000 against $5,685,000 a year ago. Net loss per common share, basic and diluted was $10.15 against $6.30 a year ago. For the six months, the company reported revenue was $3,956,000. Loss from operations was $15,709,000 against $11,633,000 a year ago. Net loss was $15,657,000 against $11,490,000 a year ago. Net loss per common share, basic and diluted was $17.23 against $13.19 a year ago.